Initially, dopamine agonists were used as adjunctive therapeutic agents to levodopa, and dopamine agonists were added after the efficacy of levodopa had diminished to achieve satisfactory efficacy, while also reducing levodopa dosage and decreasing the incidence of motor fluctuation complications due to long-term levodopa use. Recently, the discovery of a possible direct protective effect of dopamine agonists on dopamine neurons suggests that they may slow the progression of Parkinson’s disease, and therefore advocates the use of dopamine agonists first in early Parkinson’s disease patients under the age of 65-70 years who require symptomatic treatment. Some studies have demonstrated that dopamine agonists have comparable efficacy to levodopa in the first six months. In this way, the purpose of delaying the use of levodopa can be achieved, and also delaying the time when levodopa causes motor complications. We recommend that the use of DR agonists should be started at a small dose and gradually increased to an appropriate dose to avoid various recent side effects. Four dopamine agonists are available in our market, two of which are ergot DD bromocriptine and Crepa, which are no longer recommended, and two of which are non-ergot DD pramipexole and Tysudar. Tysudar, a dopamine D2 and D3 agonist, is effective in tremor, tonicity, and hyperkinesia, and somewhat more effective in tremor. Like the three agonists mentioned above, it can be used either alone or as an adjunct to levodopa treatment. The dosage form is 50 mg/tablet. Since the drug is an extended-release tablet, it should be swallowed whole and not chewed. Side effects include mild gastrointestinal reactions and, in a small number of patients, postural hypotension. Pramipexole is also a dopamine D2 and D3 receptor agonist, which has good effect on tremor, hypermobility and muscle tonicity of Parkinson’s disease, and can be used alone or in combination with levodopa. The common dose is 0.25mg~1mg/dose, 3 times a day. The maximum is 4.5mg/day, divided into 3 doses. In addition to improving motor symptoms, pramipexole is also effective for patients with depressed mood, irritability and other symptoms of depression and anxiety. It can also improve sleep for those with insomnia. Common side effects are increased sleep, dizziness and nausea, which are generally mild and well tolerated. Dose adjustment of the above mentioned drugs should be done under the guidance of a doctor. As an adjunctive treatment to levodopa, care should be taken to reduce the dosage of levodopa to reduce the side effects of levodopa.